Matches in SemOpenAlex for { <https://semopenalex.org/work/W339474882> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W339474882 endingPage "12" @default.
- W339474882 startingPage "6" @default.
- W339474882 abstract "In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone. Overall survival, the primary end point of the study, was significantly improved in patients receiving the irinotecan treatment. Only 14% of patients receiving BSC alone were alive at 1 year compared with 36% in the irinotecan group. After adjustment for prognostic factors such as performance status, the difference in survival favoring irinotecan remained highly significant (P = .001). The benefit of irinotecan was also observed through significantly longer survival without performance status deterioration, longer survival without more than 5% weight loss, and longer duration of pain-free survival. Appreciable deterioration in global quality of life (50% reduction from baseline) occurred significantly later in the irinotecan-treated patients than in the controls. Additionally, quality of life analyses of all symptoms, except diarrhea, mean scores were significantly in favor of patients assigned to irinotecan treatment than those assigned to BSC. This is the first time that the benefit of second-line chemotherapy has been demonstrated by a randomized controlled trial in advanced colorectal cancer." @default.
- W339474882 created "2016-06-24" @default.
- W339474882 creator A5057158252 @default.
- W339474882 creator A5072699629 @default.
- W339474882 date "1999-02-01" @default.
- W339474882 modified "2023-09-23" @default.
- W339474882 title "A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group." @default.
- W339474882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10213009" @default.
- W339474882 hasPublicationYear "1999" @default.
- W339474882 type Work @default.
- W339474882 sameAs 339474882 @default.
- W339474882 citedByCount "32" @default.
- W339474882 countsByYear W3394748822013 @default.
- W339474882 countsByYear W3394748822014 @default.
- W339474882 countsByYear W3394748822016 @default.
- W339474882 countsByYear W3394748822017 @default.
- W339474882 countsByYear W3394748822019 @default.
- W339474882 crossrefType "journal-article" @default.
- W339474882 hasAuthorship W339474882A5057158252 @default.
- W339474882 hasAuthorship W339474882A5072699629 @default.
- W339474882 hasConcept C121608353 @default.
- W339474882 hasConcept C126322002 @default.
- W339474882 hasConcept C141071460 @default.
- W339474882 hasConcept C143998085 @default.
- W339474882 hasConcept C159110408 @default.
- W339474882 hasConcept C168563851 @default.
- W339474882 hasConcept C203092338 @default.
- W339474882 hasConcept C2776694085 @default.
- W339474882 hasConcept C2776907518 @default.
- W339474882 hasConcept C2779951463 @default.
- W339474882 hasConcept C2780259306 @default.
- W339474882 hasConcept C2780456651 @default.
- W339474882 hasConcept C526805850 @default.
- W339474882 hasConcept C71924100 @default.
- W339474882 hasConceptScore W339474882C121608353 @default.
- W339474882 hasConceptScore W339474882C126322002 @default.
- W339474882 hasConceptScore W339474882C141071460 @default.
- W339474882 hasConceptScore W339474882C143998085 @default.
- W339474882 hasConceptScore W339474882C159110408 @default.
- W339474882 hasConceptScore W339474882C168563851 @default.
- W339474882 hasConceptScore W339474882C203092338 @default.
- W339474882 hasConceptScore W339474882C2776694085 @default.
- W339474882 hasConceptScore W339474882C2776907518 @default.
- W339474882 hasConceptScore W339474882C2779951463 @default.
- W339474882 hasConceptScore W339474882C2780259306 @default.
- W339474882 hasConceptScore W339474882C2780456651 @default.
- W339474882 hasConceptScore W339474882C526805850 @default.
- W339474882 hasConceptScore W339474882C71924100 @default.
- W339474882 hasIssue "1 Suppl 5" @default.
- W339474882 hasLocation W3394748821 @default.
- W339474882 hasOpenAccess W339474882 @default.
- W339474882 hasPrimaryLocation W3394748821 @default.
- W339474882 hasRelatedWork W1927999720 @default.
- W339474882 hasRelatedWork W1970193197 @default.
- W339474882 hasRelatedWork W1987147261 @default.
- W339474882 hasRelatedWork W2003872607 @default.
- W339474882 hasRelatedWork W2010991676 @default.
- W339474882 hasRelatedWork W2026328968 @default.
- W339474882 hasRelatedWork W2046556377 @default.
- W339474882 hasRelatedWork W2047348737 @default.
- W339474882 hasRelatedWork W2251710557 @default.
- W339474882 hasRelatedWork W2399912137 @default.
- W339474882 hasVolume "26" @default.
- W339474882 isParatext "false" @default.
- W339474882 isRetracted "false" @default.
- W339474882 magId "339474882" @default.
- W339474882 workType "article" @default.